98276-75-6Relevant articles and documents
TAM KINASE INHIBITORS
-
Paragraph 0230, (2019/02/02)
Described herein are compounds, methods of making such compounds, pharmaceutical compositions, and medicaments comprising such compounds, and methods of using such compounds to treat diseases, such as cancer.
PYRIDOPYRIMIDINONE INHIBITORS OF KINASES
-
Paragraph 0488, (2013/09/12)
The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts, wherein R1, R2, R3, R4, and B are defined in the description. The present invention relates also to compositions cont
Structure-activity relationship studies of ethyl 2-[(3-methyl-2,5-dioxo(3-pyrrolinyl))amino]-4-(trifluoromethyl)pyrimidine- 5-carboxylate: An inhibitor of AP-1 and NF-κB mediated gene expression
Palanki, Moorthy S.S.,Gayo-Fung, Leah M.,Shevlin, Graziella I.,Erdman, Paul,Sato, Mark,Goldman, Mark,Ransone, Lynn J.,Spooner, Cheryl
, p. 2573 - 2577 (2007/10/03)
Several analogues of ethyl 2-[(3-methyl-2,5-dioxo(3-pyrrolinyl))amino]-4-(trifluoromethyl)pyrimidine- 5-carboxylate (1) were synthesized and tested as inhibitors of AP-1 and NF-κB mediated transcriptional activation in Jurkat T cells. From our SAR work, ethyl 2-[(3-methyl-2,5-dioxo(3-pyrrolinyl))-N-methylamino]-4-(trifluoromethyl)- pyrimidine-5-carboxylate was identified as a novel and potent inhibitor.